Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis
- Conditions
- End-Stage Kidney Disease
- Registration Number
- NCT00062699
- Lead Sponsor
- Abbott
- Brief Summary
To evaluate the survival benefit associated with Zemplar therapy as compared to Calcijex for the treatment of secondary hyperparathyroidism in subjects with Stage V chronic kidney disease on hemodialysis as measured by time to death.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 2200
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Time to Death
- Secondary Outcome Measures
Name Time Method Time to Death attributable to cardiovascular disease Number of hospitalizations for any cause Number of days hospitalized for any cause Number of hospitalizations due to cardiovascular disease Number of days hospitalized due to cardiovascular disease
Trial Locations
- Locations (59)
Tuscaloosa Nephrology Associates
🇺🇸Tuscaloosa, Alabama, United States
Gambro Healthcare - Inglewood
🇺🇸Inglewood, California, United States
Gambro Healthcare - Los Angeles
🇺🇸Los Angeles, California, United States
Apex Research of Riverside
🇺🇸Riverside, California, United States
East Bay Nephrology Medical Group
🇺🇸San Pablo, California, United States
Nephrology Educational Services and Research, Inc.
🇺🇸Tarzana, California, United States
Lowry DaVita Dialysis Unit
🇺🇸Denver, Colorado, United States
Stamford Nephrology
🇺🇸Stamford, Connecticut, United States
Capital Dialysis Unit
🇺🇸Washington, District of Columbia, United States
Capitol Dialysis
🇺🇸Washington, District of Columbia, United States
Scroll for more (49 remaining)Tuscaloosa Nephrology Associates🇺🇸Tuscaloosa, Alabama, United States